An observational study in Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery, sponsored by Charite University, Berlin, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.
Sponsored by Charite University, Berlin, Germany · Observational
To assess the effects on outcome of levosimendan with respect to timing of its administration on the postoperative course of high-risk cardiac surgery patients in a retrospective observational study.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 159 is below the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Charite University, Berlin, Germany is the lead sponsor of 836 studies on the registry; 129 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cardiac surgery patients
Exclusion Criteria:
Levosimendan administration within first hour of post-operative ICU admission
Drug: Levosimendan
Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
Drug: Levosimendan
In-hospital mortality
Time frame: until discharge, an average of 3 weeks length of stay
1 year follow-up mortality
Time frame: 1 year after surgery
Duration of mechanical ventilation
Time frame: until discharge, an average of 3 weeks length of stay
Incidence of renal dysfunction
Time frame: until discharge, an average of 3 weeks length of stay
Incidence of renal replacement therapy
Time frame: until discharge, an average of 3 weeks length of stay
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany